Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 10/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986350 | 0.86 | LRRK2 (0.37) | KCNN4MAP4K3 | |
| SCHEMBL4406272 | 0.81 | FGFR1 (0.51) | FGFR1FGFR2FGFR3MAP4K3 | |
| SCHEMBL4404523 | 0.81 | FGFR1 (0.38) | ATRFGFR1FGFR2FGFR3CDK1 | |
| SCHEMBL4406224 | 0.78 | FGFR1 (0.48) | FGFR1FGFR2FGFR3MAP4K3 | |
| SCHEMBL988277 | 0.78 | JAK2 (0.36) | KCNN4MAP4K3 | |
| SCHEMBL4404813 | 0.78 | FGFR1 (0.46) | FGFR1FGFR2FGFR3MAP4K3 | |
| SCHEMBL4404805 | 0.78 | FGFR1 (0.46) | FGFR1FGFR2FGFR3MAP4K3 | |
| SCHEMBL4408489 | 0.78 | FGFR1 (0.46) | FGFR1FGFR2FGFR3MAP4K3 | |
| SCHEMBL13593428 | 0.76 | KCNN4 (0.38) | KCNN4 | |
| SCHEMBL4403859 | 0.76 | ATR (0.33) | ATRCDK1CDK2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101479255-B | C-MET protein kinase inhibitors for the treatment of proliferative disorders | VERTEX PHARMA | 2013-05-01 | — | — | CN | claimed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | claimed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | claimed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | ATR 1030/4885FGFR1 285/4885FGFR2 323/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | ATR 1030/4885FGFR1 285/4885FGFR2 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.